Amantadine
| Drug Category | Drug | IHD Dosing | Administration Timing Around HD Session |
|---|---|---|---|
| Antivirals | Amantadine | 100mg PO Q7days | Administer Anytime During HD |
Molecular Weight (Da) | Excreted Unchanged (%) | Normal Half-Life (Hours) | ESRD Half-Life (Hours) | Plasma Protein Binding (%) | Volume of Distribution (L/kg) | Dialytic Plasma Clearance (ml/min) | % Dialyzed |
|---|---|---|---|---|---|---|---|
| 151 | 90 | 12 | 500 | 60 | 3-8 | 67 | 2-5 (low flux) |
References:
- Aronoff GR, Bennett WM, Berns JS, Brier ME, Kasbekar N, Mueller BA, et al. Drug Prescribing in Renal Failure. Philadelphia: American College of Physicians;2007.
- DrugBank [Online]. 2012 Apr 12 [cited 2012 May 6]; Available from: URL: http://www.drugbank.ca/drugs/DB00915
- Horadam V, Sharp J, Smilack J et al. Pharmacokinetics of amantadine hydrochloride in subjects with normal and impaired renal function. Annals of internal medicine 1981; 94(4 pt 1), 454-8.
- Ing T, Mahurkar S, Dunea G, Hayashi J, Klawans H, Markey W. Removal of amantadine hydrochloride by dialysis in patients with renal insufficiency. Canadian Medical Association journal 1976; 115(6), 515.
- Soung L, Ing T, Daugiradas J et al. Amantadine Hydrochloride Pharmacokinetics in Hemodialysis Patients. Annals of internal medicine 1980; 93(Part 1), 46-49.